Constarium
← Search

Omics · study · 2026

Multi-omics analysis in EGFR-mutant lung adenocarcinoma

Listed in NCBI GEO

Using genomic and transcriptomic anaysis, we have identified TP53-GOF mutations as key genomic alterations associated with early resistance to first-line osimertinib therapy in EGFR-mutant NSCLC.

Description

Through comprehensive genomic and transcriptomic profiling, we found that TP53-GOF mutations define a biologically distinct subgroup marked by significantly shorter progression-free survival against osimrtinib treatment.

Links

Topics

From keywords
Life Sciences
Inferred from text
Genetics 72%
Provenance · 1 source records, 8 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE29705712 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[field].anzsrc:group:3105enrichment · NCBI GEOtaxonomy-embedding@1.1.0title+keywords+description (72%)
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title